期刊文献+

2009年《美国国立综合癌症网络头颈部癌临床实践指南》中国版解读 被引量:5

原文传递
导出
摘要 2009年3月底,第二届美国国立综合癌症网络(NationalComprehensiveCancerNetwork,NCCN)亚洲学术会议暨2009NCCN指南中国版修订会暨亚洲学术共识制定会在北京召开。NCCN是21家全美著名癌症中心组成的非营利性学术联盟,组织的宗旨:为医生和患者提供当前最佳的治疗建议,改善和提高对肿瘤患者的治疗水平。NCCN建立了“制订和定期更新NCCN指南一根据反馈针对性推动临床应用指南”的体系,来推动临床肿瘤诊治水平的规范和提高。其制订的《NCCN肿瘤学临床实践指南》不仅是美国肿瘤领域临床决策的标准,也逐渐成为全球肿瘤临床实践中应用最为广泛的指南,在中国也得到了广大肿瘤医生的认可与青睐。
作者 张彬 唐平章
出处 《中华耳鼻咽喉头颈外科杂志》 CAS CSCD 北大核心 2009年第9期707-709,共3页 Chinese Journal of Otorhinolaryngology Head and Neck Surgery
  • 相关文献

参考文献10

  • 1Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol, 2008, 26:3138-3146.
  • 2Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma : Three meta-analyses of updated individual data. Lancet, 2000, 355:949-955.
  • 3Adelstein D J, Li Y, Adams GL comparison of stardard radiation et al. An intergroup phase Ⅲ therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol, 2003, 21 : 92-98.
  • 4Fountzilas G, Ciuleanu E, Dafni U, et al. Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase Ⅲ Study. Med Oncol, 2004,21:95-107.
  • 5Bonner JA, Harari PM, Girah J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of head and neck. N Engl J Med, 2006,354:567-578.
  • 6Herbst RS, Arquette M, Shin DM, et al. Phase Ⅱmuhicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol,2005,23:5578-5587.
  • 7Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of eancurrant postoperative radiation plus chemotherapy trials of the EORTC(#22931 ) and RTOG ( #9501 ). Head Neck, 2005,27 : 843-850.
  • 8Jeremic B, Milicic B, Dagovic A, et al. Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck. J Clin Oncol, 2004, 22:3540-3548.
  • 9黄晓东,易俊林,高黎,徐国镇,金晶,杨伟志,卢泰祥,吴少雄,吴仁瑞,胡伟汉,谢伟长,韩非,高远红,高剑铭,潘建基,陈传本,朗锦义,李涛,董昱,付玉彬,樊林,李柏森,黎静,王晓怀,陈炳旭,高献书,张萍,吴湘玮,胡炳强.抗表皮生长因子受体单克隆抗体h—R3联合放疗治疗晚期鼻咽癌的Ⅱ期临床研究[J].中华肿瘤杂志,2007,29(3):197-201. 被引量:99
  • 10Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol, 2006, 24:5414-5418.

二级参考文献16

  • 1王树森,管忠震,向燕群,姜文奇,林桐榆,张力.表皮生长因子受体酪氨酸激酶抑制剂Gefitinib对鼻咽癌荷瘤裸鼠移植瘤生长作用的实验研究[J].癌症,2004,23(z1):1365-1369. 被引量:9
  • 2严洁华 徐国镇 见:殷蔚伯 谷铣之主编.鼻咽癌[A].见:殷蔚伯,谷铣之主编.肿瘤放射治疗学[C].北京:中国协和医科大学出版社,2002.559-562.
  • 3International Nasopharynx Cancer Study Group. VUMCA trial:preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage Ⅳ (≥ N2, M0 ) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival, Int J Radiat Oncol Biol Phys, 1996, 35: 463-469.
  • 4O'Meara WP, Lee N. Advances in nasopharyngeal carcinoma. Curr Opin Oneol, 2005, 17 : 225-230.
  • 5Lage A, Crombet T, Gonzalez G. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology. Ann Med, 2003, 35: 327-336.
  • 6DobashiY, Stren DF. Membrane-anchored forms of EGF stimulate focus formation and intercellular communication. Oncogene, 1991,6: 1151-1159.
  • 7Chua DT, Nicholls JM, Sham JS, et al. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phs, 2004, 59:11-20.
  • 8Seymour L. Epidermal growth factor receptor inhibitors: an update on their development as cancer therapeutics. Curr Opin lnvestig Drugs, 2003, 4: 658-666.
  • 9Needle MN. Safety experience with IMC-225, an anti-epidermal growth factor receptor antibody. Semin Oncol, 2002, 29 : 55-60.
  • 10Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 anti-epidermal growth factor receptor antibody. Clin Cancer Res, 2000, 6: 701-708.

共引文献98

同被引文献35

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部